Charles River Laboratories International (CRL) has recently undergone a series of significant events and reviews which have implications on its stock status. CRL has been both
upgraded and downgraded by
StockNews.com, making its current market position complex. This is further compounded by
Baird's decision to raise CRL's shares target based on strong financial analyses. CRL insiders have also sold a substantial US$6.2m of stock, which could possibly signal caution. Alongside this, CRL is under investigation by
Johnson Fistel LLP for the conduct of its directors and officers. In contrast, CRL's collaborations and grants, such as the one with
MatTek Corporation are considered positive developments.
FIL Ltd and
Icon Wealth Advisors LLC have also acquired stakes in the company indicative of potential confidence. However, countering this is the decision by
Argent Capital Management LLC to sell its CRL shares. CRL also announced a
Virial Vector Tech Transfer Program and has released their Q1 2024 earnings call transcript.
Envestnet Asset Management Inc. reduced their stake, and there are reports of new coverage from analysts at Mizuho and The Goldman Sachs Group.
Charles River Laboratories International CRL News Analytics from Wed, 08 Nov 2023 08:00:00 GMT to Sat, 15 Jun 2024 16:28:45 GMT -
Rating -1
- Innovation 5
- Information 7
- Rumor -3
